Know Cancer

or
forgot password

Phase II Study of Immunotherapy With Autogenous Papilloma Vaccine in Patients With Recurrent Juvenile Papilloma of the Larynx


Phase 2
1 Year
N/A
Open (Enrolling)
Both
Precancerous Condition

Thank you

Trial Information

Phase II Study of Immunotherapy With Autogenous Papilloma Vaccine in Patients With Recurrent Juvenile Papilloma of the Larynx


OBJECTIVES: I. Determine the immune response in patients with juvenile papilloma of the
larynx treated with autogenous vaccine derived from each patient's own tumor.

OUTLINE: Patients receive autogenous papilloma vaccine intradermally and subcutaneously
weekly for 20 weeks.

PROJECTED ACCRUAL: Not specified

Inclusion Criteria


DISEASE CHARACTERISTICS: Diagnosis of severe recurrent juvenile papilloma of the larynx
requiring surgery at least 4 times per year Condition must have existed for more than 1
year

PATIENT CHARACTERISTICS: Age: 1 and over Performance status: Not specified Life
expectancy: Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not
specified

PRIOR CONCURRENT THERAPY: See Disease Characteristics

Type of Study:

Interventional

Study Design:

Primary Purpose: Treatment

Principal Investigator

James M. Oleske, MD

Investigator Role:

Study Chair

Investigator Affiliation:

University of Medicine and Dentistry New Jersey

Authority:

United States: Federal Government

Study ID:

CDR0000071657

NCT ID:

NCT00002454

Start Date:

December 1971

Completion Date:

Related Keywords:

  • Precancerous Condition
  • lung papilloma
  • Papilloma
  • Precancerous Conditions

Name

Location

New Jersey Medical SchoolNewark, New Jersey  07103-2714